Anika Therapeutics (NASDAQ:ANIK) Director Steve Wheeler unloaded 11,016 shares of the stock in a transaction that occured on Wednesday, August 7th. The stock was sold at an average price of $27.01, for a total transaction of $297,542.16. Following the completion of the transaction, the director now directly owns 75,203 shares in the company. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Separately, analysts at Summer Street raised their price target on shares of Anika Therapeutics from $20.00 to $28.00 in a research note to investors on Friday, August 2nd. They now have a “buy” rating on the stock.
Shares of Anika Therapeutics (NASDAQ:ANIK) traded up 3.10% during mid-day trading on Thursday, hitting $23.63. Anika Therapeutics has a 52 week low of $9.13 and a 52 week high of $27.80. The stock’s 50-day moving average is currently $19.84. The company has a market cap of $331.2 million and a P/E ratio of 21.81.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.15. The company had revenue of $20.80 million for the quarter, compared to the consensus estimate of $17.09 million. On average, analysts predict that Anika Therapeutics will post $1.04 earnings per share for the current fiscal year.
Anika Therapeutics, Inc (NASDAQ:ANIK) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.